Erenumab-aooe Injection
Erenumab-aooe is a monthly injectable medication used to prevent migraines in adults.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Erenumab-aooe Injection: Patient Information Guide
A plain-language walkthrough of Erenumab-aooe Injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Erenumab-aooe is an injectable medication used at the ingredient level for migraine prevention in adults.
- Aimovig (subcutaneous injection) is FDA-approved for the preventive treatment of migraine in adults — both episodic (fewer than 15 migraine days per month) and chronic (15 or more migraine days per month) migraine.
⚙️How it works▾
Erenumab-aooe is a human monoclonal antibody — a precision protein designed to latch onto a specific target. It binds to and blocks the calcitonin gene-related peptide (CGRP) receptor. CGRP is a naturally occurring chemical that plays a central role in starting migraines. By blocking the receptor where CGRP would normally attach, erenumab-aooe helps interrupt the migraine process before it begins.
💊How it's taken▾
Aimovig is injected subcutaneously (just under the skin) once a month. It can be self-administered in the abdomen, thigh, or upper arm using a prefilled autoinjector or prefilled syringe — both are single-dose devices. There is no food restriction. Before injecting, let Aimovig sit at room temperature for at least 30 minutes away from direct sunlight.
- If you miss a dose, give it as soon as you can, then resume monthly dosing from that date.
- Do not shake the device, and inspect the solution before use — do not use if it looks cloudy, discolored, or has particles.
🤒Side effects — in detail▾
The most commonly reported side effects of Aimovig in clinical studies were:
- Injection site reactions — pain, redness, or itching where the shot was given
- Constipation
- Muscle cramps or spasms
More serious reactions — including severe constipation requiring hospitalization, high blood pressure, severe allergic reactions (anaphylaxis, angioedema), and Raynaud's phenomenon — have been reported after the medication was approved. Contact your doctor right away if you experience any of these.
⚠️Warnings & precautions▾
- Serious allergic reactions: Anaphylaxis (life-threatening allergic reaction) and angioedema (severe swelling) have been reported. These can occur within hours or more than a week after a dose. Stop Aimovig and get emergency help immediately if this happens.
- Severe constipation: Constipation can become serious — in some cases requiring hospitalization or surgery. Risk may be higher if you also take medications that slow gut movement. Tell your doctor at the first sign of significant constipation.
- High blood pressure: New or worsening high blood pressure has been reported, most often within seven days of a dose. Your doctor should monitor your blood pressure during treatment.
- Raynaud's phenomenon: This condition — where blood vessels in the fingers or toes tighten excessively, causing color changes, pain, or numbness — has been reported. Stopping Aimovig usually resolves symptoms, but seek evaluation if symptoms persist.
🔀What it interacts with▾
Erenumab-aooe has a low risk of drug interactions overall, but there are a few things worth knowing:
- Medications that slow the gut (decrease gastrointestinal motility) — combining these with Aimovig may increase the risk of severe constipation or related complications.
- Oral contraceptives — Aimovig did not affect the blood levels of a combined oral contraceptive (ethinyl estradiol / norgestimate) in a study, so standard birth control pill effectiveness is not expected to be changed.
- Sumatriptan (a common migraine relief medication) — Aimovig did not affect how sumatriptan behaves in the body, and the combination had no effect on resting blood pressure compared to sumatriptan alone.
- Cytochrome P450 enzyme-based interactions — Aimovig is not broken down by these liver enzymes, so interactions with many common medications through this common pathway are unlikely.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Serious allergy to erenumab-aooe or its ingredients: Do not use Aimovig if you have had anaphylaxis or angioedema from it — it is contraindicated.
- History of constipation or gut motility issues: Tell your doctor, as serious constipation is a known risk.
- High blood pressure or risk factors for it: Aimovig can cause new or worsening high blood pressure.
- Raynaud's phenomenon: Patients with a history of this condition should be monitored closely — it may worsen or recur.
- Pregnancy: There are no adequate human safety data. A pregnancy registry is available (call 1-833-244-4083 or visit the registry website) for women exposed during pregnancy.
- Breastfeeding: It is not known whether erenumab-aooe passes into breast milk. Discuss the benefits and risks with your doctor.
- Children: Safety and effectiveness in pediatric patients have not been established.
- Older adults (65+): Clinical studies did not include enough older patients to draw firm conclusions; your prescriber will start cautiously and monitor closely.
- Severe kidney impairment: Patients with severely reduced kidney function have not been studied; inform your prescriber.
📡Pharmacodynamics — effects in the body▾
In a controlled study in healthy volunteers, giving erenumab-aooe together with sumatriptan (a common migraine rescue drug) had no effect on resting blood pressure compared with sumatriptan given alone. This suggests the combination does not add cardiovascular blood pressure risk beyond sumatriptan alone. Aimovig is designed specifically for subcutaneous (under-the-skin) use.
🔬Pharmacokinetics — how your body processes it▾
After a subcutaneous injection, erenumab-aooe reaches peak blood levels in approximately 6 days, with an estimated bioavailability (how much of the dose actually reaches the bloodstream) of 82%. The drug has an effective half-life of 28 days — meaning it stays active in the body for roughly a month, which is why it is dosed once monthly. Steady drug levels in the blood are typically reached after about 3 months of regular dosing. The body clears it through two pathways: at lower concentrations, it is removed mainly by binding to its CGRP receptor target, while at higher concentrations it is broken down through a general protein-digestion process. Age, sex, race, and whether a patient has episodic or chronic migraine do not meaningfully affect how the drug is processed.
📦How to store it▾
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. refrigerator, AIMOVIG should be kept at room temperature (up to 25°C ) in the original carton and must be used within 7 days. Do not freeze.
📄 Written from Erenumab-aooe Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Erenumab-aooe Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly does Aimovig do — does it stop a migraine once it starts? ▾
How long does it take before I notice fewer migraines? ▾
I'm worried about constipation — how serious can it be? ▾
Can I take my usual migraine pills (like sumatriptan) at the same time as Aimovig? ▾
Is it safe to use Aimovig if I'm pregnant or trying to get pregnant? ▾
What signs should make me call my doctor or stop using Aimovig? ▾
Is Erenumab-aooe Injection available over the counter? ▾
When was Erenumab-aooe Injection first available? ▾
Who makes Erenumab-aooe Injection? ▾
💬 Answers drafted from Erenumab-aooe Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Erenumab-aooe Injection comes
Erenumab-aooe Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Aimovig is indicated for the preventive treatment of migraine in adults
- Aimovig is given as a subcutaneous (under-the-skin) injection once monthly
- Aimovig should be allowed to sit at room temperature for at least 30 minutes before injecting — keep it out of direct sunlight during this time
- Aimovig is injected subcutaneously into the abdomen, thigh, or upper arm; do not inject into skin that is tender, bruised, red, or hard
- Aimovig is available as a single-dose prefilled autoinjector or a single-dose prefilled syringe — both deliver the entire dose and are for one-time use only
- Do not shake Aimovig; check the solution before use and do not use it if it appears cloudy, discolored, or contains particles
📊 Erenumab-aooe Injection across the U.S. market
How Erenumab-aooe Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Erenumab-aooe Injection is used
A general measure of how commonly Erenumab-aooe Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Erenumab-aooe Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Erenumab-aooe Injection prescribed? Of the 1,596 medications we measure, Erenumab-aooe Injection ranks #408 by Medicaid prescriptions — more than 74% of them.
Utilization by Erenumab-aooe Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
1 ML erenumab-aooe 140 MG/ML Auto-Injector Most dispensed
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2120193
1 ML erenumab-aooe 70 MG/ML Auto-Injector
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2045636
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Erenumab-aooe Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 2 of 3 listed Erenumab-aooe Injection NDCs with Medicaid activity.
🔍 Compare Erenumab-aooe Injection products
A representative set of FDA-listed product records for Erenumab-aooe Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 70 mg/mL | Subcutaneous | Amgen, Inc × 2 listings | BLA | View NDC → |
| 140 mg/mL | Subcutaneous | Amgen, Inc × 2 listings | BLA | View NDC → |
| 70 mg/mL | Subcutaneous | Amgen Inc × 6 listings | BLA | View NDC → |
| 140 mg/mL | Subcutaneous | Amgen Inc × 6 listings | BLA | View NDC → |
Showing 16 of 16 products — FDA National Drug Code Directory. See every product, package size and price: browse all 16 Erenumab-aooe Injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Erenumab-aooe Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Erenumab-aooe Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Erenumab-aooe Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2045613 2 dose forms · 4 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 2045635In current FDA listingsClinical drug / strength (SCD) 1 ML erenumab-aooe 140 MG/MLRxCUI 21201931 ML erenumab-aooe 70 MG/MLRxCUI 2045636 -
Dose form (SCDF) Prefilled Syringe RxCUI 2045617No current FDA listingClinical drug / strength (SCD) 1 ML erenumab-aooe 140 MG/MLRxCUI 21201981 ML erenumab-aooe 70 MG/MLRxCUI 2045627
Look up RxCUI 2045613 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Erenumab-aooe Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Erenumab-aooe Injection belongs to the Calcitonin gene-related peptide (CGRP) antagonists class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Amgen Inc is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.